Table 2.
Published case reports and case series regarding COVID-19 vaccine-associated myocarditis that describe LGE on cardiac magnetic resonance imaging (MRI).
| Age | Sex | Vaccine types | Number of vaccinations | Time from last vaccination to cardiac MRI | LGE: layer | LGE: segment | ||
|---|---|---|---|---|---|---|---|---|
| Marshall et al. | Case 1 | 16 | Male | Pfizer | 2nd | NA | Subepicardia | Apical and midchamber lateral wall |
| Case 2 | 19 | Male | Pfizer | 2nd | NA | Mid wall | Basal inferolateral wall | |
| Case 3 | 17 | Male | Pfizer | 2nd | NA | Subepicardial | Basal anterolateral segment, basal to midventricular inferolateral segments | |
| Case 5 | 17 | Male | Pfizer | 2nd | NA | Epicardia | Anterior and lateral LV | |
| Case 7 | 14 | Male | Pfizer | 2nd | 5 days | Subepicardial | Mid and apical left ventricle free wall | |
| Rosner et al. | Case 2 | 39 | Male | Pfizer | 2nd | 11 days | Subepicardial | Along the anterior and lateral walls |
| Case 3 | 39 | Male | Modelna | 2nd | 5 days | Subepicardial and midmyocardial | Anterior wall | |
| Case 4 | 24 | Male | Pfizer | 1st | 7 days | Midmyocardial | Septal and inferior walls | |
| Male | Subepicardial | Anterior, lateral, and inferior walls | ||||||
| Case 5 | 19 | Male | Pfizer | 2nd | 3 days | Multifocal patchy subepicardial and midmyocardial | Lateral and inferolateral walls | |
| Case 6 | 20 | Male | Pfizer | 2nd | 6 days | Subepicardial | Lateral, inferolateral, anterolateral walls, apex | |
| Case 7 | 23 | Male | Pfizer | 2nd | 3 days | Mid wall | Basal anteroseptal | |
| Mouch et al. | Case 1 | 24 | Male | Pfizer | 2nd | NA | Subepicardial | Basal septum |
| Mid myocardial | Inferolateral | |||||||
| Case 2 | 20 | Male | Pfizer | 2nd | NA | Subepicardial | Basal and middle anterolateral and inferolateral walls | |
| Case 3 | 29 | Male | Pfizer | 2nd | NA | Diffuse | Basal, inferolateral, anterolateral and anteroseptal walls | |
| Case 4 | 45 | Male | Pfizer | 1st | NA | Subepicardial | Middle anterolateral, inferolateral and apical anterior walls | |
| Case 5 | 16 | Male | Pfizer | 2nd | NA | Midmyocardial | Basal inferolateral | |
| Male | Subepicardial | Middle anterolateral | ||||||
| Case 6 | 17 | Male | Pfizer | 2nd | NA | Subepicardial | Basal inferolateral, middle inferolateral and infero-septal and apical lateral, anterior and inferior walls | |
| Mid-myocardial | Middle inferolateral and anterolateral and apical anterior and lateral walls | |||||||
| Kim et al. | Case 1 | 36 | Male | Moderna | 2nd | 3 days | Epicardial | Apical lateral |
| Case 4 | 24 | Male | Pfizer | 2nd | 3 days | Epicardial, patchy | Lateral | |
| Ammirati et al. | 56 | Male | Pfizer | 2nd | NA | Subepicardial-intramyocardial regions | Basal and apical segments of the infero-lateral wall | |
| Angelo et al. | 30 | Male | Pfizer | 2nd | 6 days | Subepicardial | Sparing of the basal and mid-septal segments | |
| Albert et al. | 24 | Male | Moderna | 2nd | 5 days | Mid-myocardial and epicardial | Lateral, anterolateral and inferolateral segments | |
| Muthukumar et al. | 52 | Male | Moderna | 2nd | 6 days | Midmyocardial and subepicardial | Infero-septal, inferolateral, anterolateral, and apical walls | |
| Subepicardial | Inferior basal and mesocardial midventricular region | |||||||
| Minocha et al. | 17 | Male | Pfizer | 2nd | NA | Subepicardial | Mid-lateral and apical | |
| Mansour et al. | Case 1 | 25 | Male | Moderna | 2nd | 6 days | Subepicardial | Anterolateral wall of the mid and apical left ventricle |
| Case 2 | 21 | Female | Moderna | 2nd | 4 days | Subepicardial | Inferolateral wall at the base | |
| Habib et al. | 37 | Male | Pfizer | 2nd | NA | Subepicardial | Basal lateral wall | |
| Cereda et al. | 21 | Male | Pfizer | 2nd | NA | Patchy epicardial | The posterior, anterior, inferior, and lateral walls | |
| Vidula et al. | Case 1 | 19 | Male | Pfizer | 2nd | NA | Subepicardial | Basal to mid lateral wall |
| Case 2 | 18 | Male | Moderna | 2nd | NA | Subepicardial | Mid lateral wall | |
| Williams et al. | 34 | Male | Moderna | 2nd | 7 days | Subepicardial | Anterolateral and inferolateral segments | |
| Isaak et al. | 15 | Male | Pfizer | 2nd | NA | Subepicardial | Inferolateral wall | |
| Hasnie et al. | 22 | Male | Moderna | 1st | NA | Subepicardial | Lateral wall and inferior segments at the midventricular and apical LV | |
| Patrignani et al. | 56 | Male | Pfizer | 1st | 11 days | Sub-epicardial | Basal and middle segments of the infero-lateral wall | |
| Kim et al. | 24 | Male | Pfizer | 2nd | NA | Sub-epicardial | Basal inferior and inferolateral segment | |
| Ehrlich et al. | 40 | Male | Pfizer | 1st | 12 days | Diffuse | Basal and mid anteroseptal and inferoseptal segments as well as in the apical septal segment | |
| Patel et al. | Case 1 | 22 | Male | Pfizer | 1st | NA | Subepicardial | Basal inferior, basal inferolateral, and apical lateral |
| Case 2 | 19 | Male | Pfizer | 2nd | NA | Subepicardial | Basal inferolateral | |
| Case 3 | 25 | Male | Moderna | 2nd | NA | Subepicardial | Lateral | |
| Case 4 | 37 | Male | Pfizer | 2nd | NA | Subepicardial | Basal anteroseptal segment | |
| Case 5 | 20 | Male | Pfizer | 2nd | NA | Subepicardial and mid-myocardial | Basal, mid, and apical lateral segments | |
| Tailor et al. | 44 | Male | Moderna | 2nd | 5 days | Mid-myocardial | Mid-septum, infero-septum, and inferior walls at the base to midventricle | |
| Sub-epicardial and mid-myocardial | Lateral wall at the mid-ventricle and apical lateral wall | |||||||
| Nguyen et al. | 20 | Male | Moderna | 1st | NA | Subepicardial | Mid and basal inferolateral segments | |
| Onderko et al. | Case 2 | 28 | Male | Pfizer | 2nd | NA | Epicardium | Apical lateral wall, midanterolateral segments |
| Case 3 | 36 | Male | Moderna | 2nd | NA | Epicardial | Mid- to distal inferolateral and lateral walls | |
| Shiyovich et al. | Case 1 | 41 | Male | Pfizer | 2nd | 107 days | Mid-wall | Inferolateral (basal) |
| Case 2 | 24 | Male | Pfizer | 2nd | 103 days | Mid-wall and epicardia | Inferolateral (basal) | |
| Case 3 | 17 | Male | Pfizer | 2nd | 7 days | Epicardial | Inferolateral, anterolateral, (basal to apical) | |
| Case 4 | 37 | Male | Pfizer | 1st | 48 days | Epicardial | Inferolateral (basal, mid) | |
| Case 5 | 39 | Male | Pfizer | 2nd | 8 days | Mid-wall and epicardia | Inferoseptal, anteroseptal (basal), inferolateral, anterolateral (basal), Inferolateral (med), septum, lateral (apical) | |
| Case 7 | 19 | Male | Pfizer | 2nd | 43 days | Mid-wall | Inferior (apicalbasal), Inferolateral (mid, basal), anterior (basal, mid), septum, lateral (apical) | |
| Case 8 | 28 | Male | Pfizer | 2nd | 139 days | Mid-wall | Inferolateral, anterolateral (basal) | |
| Case 10 | 17 | Male | Pfizer | 2nd | 17 days | Epicardial | Inferior, inferolateral (basal), inferior, inferoseptal, inferolateral (mid) | |
| Case 11 | 36 | Male | Pfizer | 1st | 63 days | Mid-wall | Lateral (apical) | |
| Case 12 | 27 | Male | Pfizer | 2nd | 105 days | Epicardial | Inferolateral (basal) | |
| Case 13 | 42 | Male | Pfizer | 1st | 53 days | Epicardial | Inferolateral (apical, basal), anterolateral (basal) | |
| Case 14 | 76 | Male | Pfizer | 2nd | 117 days | Mid-wall | Inferolateral (basal) | |
| Case 15 | 32 | Male | Pfizer | 2nd | 83 days | Mid-wall | Inferior (basal), inferolateral (basal) | |
| Our Cases | Case 1 | 19 | Male | Moderna | 2nd | 5 days | Sub-epicardial | Infero-lateral (basal-mid) |
| Case 2 | 20 | Male | Moderna | 2nd | 45 days | Mid-wall | Inferior (basal) | |
| Case 3 | 29 | Male | Moderna | 2nd | 12 days | mid-wall | Anterior, inferior wall | |
| Case 4 | 48 | Male | Pfizer | 1st | 12 days | Mid-wall | Inferior walls at the base to midventricle | |
| Subepicardial | Mid-septum, and infero-septum of left ventricular Wall |
LGE, late-gadolinium enhancement; LV, left ventricular.